Updated:
Aktana
Derek Choy leads Aktana, an AI platform orchestrating HCP engagement for 350+ pharma brands, now part of PharmaForceIQ.
Aktana
Aktana was built for a specific, regulated workflow: making every pharmaceutical sales and medical affairs interaction context-aware. The company’s software delivers AI-driven suggestions to field teams, prioritizing which healthcare professionals to engage and how. By integrating data across brands and channels, Aktana gives reps and medical science liaisons a unified view of each HCP relationship. The platform spans three primary domains — commercial brand teams, medical affairs, and medtech — and handles strategy orchestration alongside automated intelligence. Its results are quantified publicly: a 14% sales growth during an oncology drug launch using AI-based HCP segmentation, $30 million in projected annual upside unlocked for a client through next-best-action triggers, and a 40% increase in approved HCP emails among high-adopter reps. Confirmed deployments include use by a top-10 biopharma company and a mid-sized biotech firm, with evidence spanning the United States (per Aktana website, 2026). Aktana serves more than 10,000 platform users and has delivered over 30 million unique suggestions across 75-plus use-case libraries. The company operates from San Francisco and was acquired by PharmaForceIQ to combine Aktana’s AI layer with digital orchestration capabilities. January 2026: PharmaForceIQ acquired Aktana to deliver cross-functional engagement impact for pharmaceutical clients (per Aktana website, 2026). The acquisition by PharmaForceIQ marks a structural shift: Aktana evolved from a standalone AI copilot for sales teams into the intelligence core of a broader commercial orchestration platform. Its architecture — a proprietary blended-AI engine built on patents covering key innovations — was designed to feed field-level feedback back into strategy, making campaign adjustments measurable in weeks rather than quarters.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
San Francisco
Corporate office
San Francisco, CA, United States
Principals
Derek Choy
Chief Executive Officer (inferred from executive authorship)
Sector focus
Frequently asked questions
What does Aktana's AI actually do for pharmaceutical sales teams?
Aktana serves proprietary blended-AI suggestions to field reps and medical science liaisons, recommending which healthcare professionals to contact, through which channel, and with what content. The system ingests brand strategy, historic engagement data, and external signals to serve next-best-action nudges. For one oncology client, AI-based HCP segmentation contributed to a 14% sales lift during an indication launch (per Aktana website, 2026).
How did the PharmaForceIQ acquisition change Aktana's structure?
PharmaForceIQ acquired Aktana in January 2026, combining Aktana's AI-driven HCP intelligence layer with PharmaForceIQ's digital orchestration platform. The combined entity positions Aktana's technology as the analytical engine within a broader suite that spans commercial, medical, and medtech engagement. Operationally, this moves Aktana from a standalone tool into integrated cross-functional orchestration workflows.
Which life sciences functions does Aktana serve?
Aktana's platform is configured for three distinct business lines: commercial brand teams optimizing sales and marketing, medical affairs teams managing HCP education and scientific exchange, and medtech companies coordinating account-level commercial execution. This segmentation reflects the different regulatory and engagement models across pharmaceutical sales, medical science liaison work, and device marketing.
What measurable outcomes has Aktana reported for clients?
Publicly cited results include a 14% sales increase nine months after deployment for a top-10 biopharma client, $30 million in projected annual upside from next-best-action recommendations for another client, a 40% lift in approved HCP emails among high-adopter reps, and approximately $8 million in annualized incremental sales directly attributed to next-best-action suggestions (per Aktana website, 2026).
How does Aktana handle compliance within pharma HCP engagement?
Aktana's platform operates within the strict regulatory frameworks governing life sciences promotion and medical communication. Its recommendations are designed to be compliant and leave final decisions with human reps. The system enforces business rules around approved content, channel permissions, and HCP consent, while maintaining audit trails that support transparency requirements.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: